



#FutureFresenius – Advancing Patient Care

Credit Presentation – November 2023

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

1 Company overview

- 2 Strategic update
- 3 Financial review, priorities & outlook FY/23
- 4 Credit highlights

Our purpose for #FutureFresenius – Advancing Patient Care



Advancing Patient Care

A global leader in healthcare products and services



Group revenue and number of employees are shown excl. FMC

Global trends offer growth opportunities for Fresenius

4x



Global spending on health

More than 10% of global GDP will be spent on healthcare¹



97%

of data produced by hospitals remains unused³

Managing health data

More than 30% of global data is generated by Life Science and Healthcare and only 2% of data produced is retained the following year⁴

Generic drugs

save the US healthcare system⁶



\$338bn

p.a.

Aging Population

In 2020, 1bn people worldwide were >60 years²

+40%

to 1.4bn until 2030



\$23.1bn

Total funding in 2021

Healthcare investments reach record highs

\$23.1bn was raised by biopharma companies worldwide with a surge in venture investment and fundraising⁵

...while the European healthcare system saves⁷

€100bn

p.a.



Sources: ¹ WHO, Global spending (2022), ² WHO, Ageing and health (2022), ³ Deloitte, Health Data (2023), ⁴ Deloitte, Health Data (2023)

⁵ World Economic Forum, Healthcare Outlook (2021), ⁶ AAM report (2021), ⁷ UBS, Longer Term Investments: Generics (2018)

#FutureFresenius – Operating Companies and Investment Companies

#FutureFresenius *Advancing Patient Care*

Operating Companies

Profitability optimization and growth



Healthcare products

for critically and chronically ill patients



Healthcare services

along the care continuum

World-class therapies through system-critical healthcare products and services

(Bio)Pharma Platform

MedTech Platform

Care Provision Platform

Investment Companies

Financial value management




Dialysis
provision
and products



Project
business
and services

Deconsolidation
effective by December 2023

At the heart of healthcare



Therapy-focused platforms – Bringing the future of healthcare to patients



1 Company overview

2 Strategic update

3 Financial review, priorities & outlook FY/23

4 Credit highlights


#FutureFresenius – ReSet delivered, pacing ReVitalization

Structural
simplification

Sharpen
focus


Accelerate
performance

✓ FMC deconsolidation to be completed by December



✓ Over-delivering on cost savings

Cost savings program delivering more quickly than forecasted



- Focus on Fresenius Group excl. FMC
- Cost savings program is delivering on 2023 targets and beyond
- FY/23 EBIT savings target already achieved in Q1-3
- Kabi as largest contributor to cost savings
- Only ~€90m of one-time costs spent in Q1-3
- Focus on achieving the full €350m savings by FY/25

✓ Clear ambitions – F³ sets framework

Fresenius Group				
	Operating Companies		Investment Companies	
	FRESENIUS KABI	FRESENIUS HELIOS	FRESENIUS MEDICAL CARE	FRESENIUS VAMED
EBIT margin	14 – 17%	9 – 11%	10 – 14%	4 – 6%
Organic revenue growth	4 – 7%	3 – 5%		
CAPITAL EFFICIENCY	CAPITAL STRUCTURE		CASH	DIVIDEND
ROIC 6 – 8%	Leverage ratio 3.0x – 3.5x		Cash Conversion Rate ¹ Around 1	Progressive dividend In line with EPS cc growth but at least on prior year level

✓ Divestment program advancing

Divestments well advancing


Fresenius exits hospital market in Peru

Fresenius sharpens focus and sells fertility services group Eugin

....

....

Fresenius Kabi – Accelerating our growth, driving performance



Healthcare services
along the care continuum



Fresenius Helios – Powerful set of care provision assets



Healthcare products
for critically and chronically ill patients



Leading healthcare services delivering value for >24 million patients yearly



€7.0B



€4.4B

- Continuing **stable margin delivery**
- Increased **focus on return on capital** and **cash flow**
- Clear **strategy** for **value creation** across portfolio
- CMD envisaged for 2Q/2024

ⓧ FY/22 Net Sales; Eugin Group no longer included in this presentation due to divestment – revenue figures thus do not add up to Helios' reported total revenue



New, more rigorous F³ – Fresenius Financial Framework

Fresenius Group

Operating Companies



**EBIT
margin**

14 – 17%

Targeting upper end of range
by 2026

9 – 11%

**Organic
revenue growth**

4 – 7%

3 – 5%

Investment Companies

FSE expectation as major shareholder



10 – 14%

4 – 6%

CAPITAL EFFICIENCY

ROIC

6 – 8%

CAPITAL STRUCTURE

Leverage ratio

3.0x – 3.5x

CASH

Cash Conversion Rate¹

Around 1


DIVIDEND

Progressive dividend

**In line with EPS cc growth
but at least on prior year level**

¹ Cash Conversion Rate – defined as adjusted FCFbIT / EBIT before special items
All figures before special items

#FutureFresenius – Delivering on our promises; quarter on quarter



1 Company overview

2 Strategic update

3 Financial review, priorities & outlook FY/23

4 Credit highlights

Q3/23: #FutureFresenius momentum continuing



Kabi and Helios deliver strong performance



Cost savings delivery ahead of schedule



Simplification advanced: FMC deconsolidation effective December



VAMED EBIT positive



Divestment program advancing




#FutureFresenius – 2023 outlook improved

Kabi and Helios: Consistent strong delivery

OPERATING COMPANIES

		Q1/23	Q2/23	Q3/23
 FRESENIUS KABI	REVENUE <small>ORG.</small>	+7% ✓	+8% ✓	+7% ✓
	EBIT	-4% ✓	+5% ✓	+6% ✓
 FRESENIUS HELIOS	REVENUE <small>ORG.</small>	+5% ✓	+7% ✓	+5% ✓
	EBIT	+2% ✓	+3% ✓	+8%

INVESTMENT COMPANY


 FRESENIUS VAMED	REVENUE <small>ORG.</small>	+13%	-7%	+13%
	EBIT	-€27m	-€20m	€10m

✓ *Within or above structural growth/margin band according to Fresenius Financial Framework*

**Group EBIT
outlook
improved
for FY/23**

Kabi and Helios at top-end of structural growth band

EBIT (MARGIN)





REVENUE (ORG. GROWTH)



KEY MESSAGES

- Strong organic **revenue growth** driven by outstanding **12%** increase in **Nutrition, Biopharma** and **MedTech**
- **EBITDA margin** of **20.1%** in Q3/23
- **EBIT margin** within structural band driven by ongoing **strong operating performance** and **cost savings**

All growth rates in constant currency (cc), before special items



- Strong organic **revenue growth** at **top-end** of growth band
- **EBIT margin solid** despite usual summer effect
- Very strong YoY **EBIT growth of 8% cc**

Improving debt profile: A top priority

**MORE
FLEXIBILITY**

**LOWER
EXPENSES**


**HIGHER
EPS**

Key efforts



Cost savings

FY/23 savings target achieved



Organic growth

Top-end of growth band



Operating gains

Operating companies in margin band YTD



**Divestments of
non-core assets**

Divestments advancing; hospital exit in Peru signed,
divestment of fertility services group Eugin signed

Advancing patient care – strong partnerships, launches and recognition

RECENT HIGHLIGHTS



Fresenius Kabi **signed agreement** with Virginia Oncology Associates to deliver **Ivenix Infusion System**

mAbxience and **Abbott** enter **strategic partnership**

Fresenius Kabi **launches** Tyenne®, the **first approved tocilizumab biosimilar** in the **European Union**

Fresenius Kabi and Lupagen enter into strategic development and supply agreement to bring **cell and gene therapies to the bedside**

Advancing patient care – delivering quality and innovative healthcare

RECENT HIGHLIGHTS



Opening of the Quirónsalud Valdebebas Medical Center in Madrid with 18 specialties, state-of-the-art facilities and a highly qualified team

Quirónsalud Málaga launches an **Advanced Clinical Research Program** with specific **International Clinical Trials** for cancer patients


Helios ENDO clinic in Hamburg pilots the use of **artificial intelligence** in building automation through **digital twin**

Launch of 3 new apprentice classes in **newly founded Helios Training and Formation Center** in Bad Saarow

Q3/23 – Strong Group performance paced by Kabi and Helios



- Start of IFRS 5 application in Q3/23 – FMC only included below EBIT
- Strong revenue growth driven by Operating Companies and Vamed
- EBIT growth reflects strong performance of Operating Companies; Vamed with operational improvement



- Higher interest expense at -€109m (Q3/22: -€67m) due to rising interest rate environment
- Tax rate of 24.1% in Q3; Q1-3/23 at 25.2% in line with FY/23 expectation (25-26%)
- Healthy operating cash flow
- Leverage ratio 15bps below Q2 at 4.03x; above target range of 3.0x to 3.5x


P&L growth rates in constant currency (cc), before special items
Net income attributable to shareholders of Fresenius SE & Co. KGaA
Net Debt/EBITDA excluding Fresenius Medical Care

Fresenius Kabi: Strong growth and margin momentum

Q3/23 results



QUARTERLY FINANCIALS



Before special items


MAIN DEVELOPMENTS

- Organic revenue growth of 7% at top-end of structural growth band
- Growth Vectors contributing combined 12% organic revenue growth (MedTech: 8%; Nutrition: 9%; Biopharma: 71%)
- Pharma with robust top-line
- Strong Q3 EBIT margin above 14% with YoY margin expansion in all business units
- EBIT improvement driven by operational leverage and excellent progress on cost and efficiency measures ahead of plan

Fresenius Helios: Usual summer effect but strong YoY improvement Q3/23 results



QUARTERLY FINANCIALS



Before special items

MAIN DEVELOPMENTS


- Consistent strong organic revenue growth YTD at top-end of structural growth band
- Performance at Helios Germany driven by solid activity levels and favorable patient mix; Helios Spain with continued healthy activity levels despite seasonal effects
- Strong 8% YoY EBIT growth and nice YoY improvement in EBIT margin – supported by cost savings progress and government relief funds
- Fertility with strong improvement YoY driven by price and mix effects

Fresenius Vamed: Back to positive operating performance

Q3/23 results



QUARTERLY FINANCIALS



Before special items

TRANSFORMATION UPDATE


- Revenue growth in Q3 driven by both Service as well as Project business
- Turnaround in EBIT led by High-End Services and Health Facility Operations
- Restructuring measures underway, clear implementation roadmap to ensure sustainable operational turnaround
- Special items of €109m booked in Q3/23 (YTD: €441m); predominantly non-cash
- Positive operating earnings expected in Q4/23
- Target to be back in structural EBIT margin band of 4% to 6% by 2025

Cost savings program delivering more quickly than forecasted

PLANNED UNTIL 2025

Cost savings | EBIT view


☐ Thereof FMC



**One-time
Costs**

~€700-750m
between 2023-2025,
thereof 1/3 FSE

FOCUS ON 2023



2/3 of FSE costs
expected to occur
in 2023

✓ ~€430m
delivered
in Q1-3

✓ ~€200m
delivered
in Q1-3

- Focus on Fresenius Group excl. FMC
- Cost savings program is delivering on 2023 targets and beyond
- FY/23 EBIT savings target already achieved in Q1-3
- Kabi as largest contributor to cost savings
- Only ~€90m of one-time costs spent in Q1-3
- Focus on achieving the full €350m savings by FY/25

Operating cash flow drives Q3/23

€m	Q3/23	Q3/22	Q3/23 LTM	Q3/22 LTM
OCF - continuing operations	648	598	2,084	1,886
% OCF Margin	11.7%	11.1%	9.3%	8.9%
Capex	-272	-223	-1,126	-1,091
Capex in % of revenue	-4.9%	-4.1%	-5.1%	-5.1%
Acquisitions	-181	-484	-237	-770
Dividends	1	--	-445	-275
Lease liabilities	-75	-46	-233	-150
FCF	121	-155	43	-400

- Q3 OCF from continuing operations (excl. FMC) increased by 8% over prior-year quarter
- Kabi: strong OCF development driven by operating performance and improved Working Capital management
- Helios: impacted by higher working capital and phasing effects in H2/22
- LTM OCF Margin at a healthy 9.3%
- CAPEX in line with FY/23 expectation of around 5%

Outlook for FY/23 improved

Fresenius Group

Revenue growth excluding FMC (organic):
Mid-single-digit growth

EBIT (cc growth) excluding FMC:
Broadly flat development
(Previously: Broadly flat-to-mid-single-digit decline)

Operating Companies



- **Mid-single-digit** organic revenue growth
- **Around 14%;** structural EBIT margin band of **14 – 17%**



- **Mid-single-digit** organic revenue growth
- **Within** structural EBIT margin band of **9 – 11%**

Investment Companies



- **With adoption of IFRS 5 outlook is provided ex FMC**
- **Performance of FMC reflected in FSE's P&L below EBIT**



- **Low-to-mid-single-digit** organic revenue growth
- **Clearly below** structural EBIT margin band of **4 – 6%**

FY/23 – Other financial KPIs for Fresenius Group

With adoption of IFRS 5 – Guidance to be provided ex FMC only:

Q1-3/23 (ex FMC)		
Profitability	Interest expense	€300m
	Tax rate	25.2%
Capital Allocation	CAPEX	4.4%
	CCR LTM	0.9
	ROIC	5.0%
	Leverage ratio	4.03x

Around the middle of the €400 to €440m range

Between 25 to 26%

Around 5%

Below 1

Around 5%


Below 4x

- 1 Company overview
- 2 Strategic update
- 3 Financial review, priorities & outlook FY/23


4 Credit highlights

Capital efficiency and returns – deleveraging remains key


ROIC



CCR¹



NET DEBT/EBITDA²



- Excluding FMC ROIC around 40 bps higher
- Q3/2023 ROIC still below 6-8% target corridor
- FY/23 is inflection point

- Q3/23: CCR stable at 0.9x (excl. FMC)
- YoY improvement from 0.7x in Q3/22 to 0.9x in Q3/23
- Increased focus on cash and cash return in the Group

- Strong commitment to 3.0 to 3.5x leverage corridor and investment grade rating
- Sequential improvement by 16 bps
- Excluding potential divestments

¹ LTM

² At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; after effects from assets held for sale at FMC

Strong balance sheet is a key pillar of #FutureFresenius: Debt reduction a priority for 2024 and beyond



Stringent capital allocation and focus on cash flow are key



Improved credit outlook by Fitch is strong testament to successful execution of #FutureFresenius



Clear commitment to Investment Grade rating and 3.0x to 3.5x leverage range



Refinancing of 2024 maturities concluded

CREDIT RATINGS

Standard & Poor's

BBB

Outlook: negative

Fitch

BBB-

Outlook: stable



Moody's

Baa3

Outlook: stable

REFINANCING ACTIVITIES FOR MAJOR 2024 MATURITIES CONCLUDED



**Schuldschein
Loan¹**

- May 2023
- **€850m**
- 3, 5 and 7 years maturities
- ESG-linked



CHF Bond

- October 2023
- **CHF275m**
- 5 years maturity
- Debut bond in CHF




Euro Bond

- October 2023
- **€500m**
- 7 years maturity


¹ Promissory note loans

Fresenius excl. FMC: prudent financing strategy and financial policy

Diversified financing mix¹



Well-balanced maturity profile^{1, 2} (€m)



¹ As of September 30, 2023, if not stated otherwise; ² Based on utilization of major financing instruments, excl. Commercial Paper and other cash management lines; ³ Calculations based on total financial debt, excluding Lease & Purchase Money Obligations; ⁴ CHF 275m 5y bond issued on October 18, 2023; ⁵ EUR 500m 7y bond issued on October 5, 2023

Financial policy highlights¹

- **Sufficient liquidity reserve:**
 - ✓ Undrawn ESG-linked revolving credit facility of €2bn
 - ✓ Committed bilateral credit facilities of ~€640m, complemented by uncommitted facilities and €1.5bn Commercial Paper program
- **Conservative fix-floating rate debt mix of ~85%/15%³**
- **Strong access to capital markets:**
 - ✓ Three different debt markets tapped in 2023 despite challenging market environment
- **Large and strong relationship banking group**
- **Proactive refinancing strategy:**
 - ✓ 2024 maturities largely pre-funded in 2023
 - ✓ Short-term debt proportion significantly reduced

Key credit highlights



Attachments

Fresenius excl. FMC: strong access to financial markets

Major financing instruments

	2017	2018	2019	2020	2021	2022	2023
Bonds	€2.6bn		€1.0bn	€750m €750m €1.0bn	€1.5bn	€1.3bn €1.0bn	CHF 275m ¹ €500m ²
Syndicated Loans	€3.8bn		€100m		€2.0bn		
Schuldschein Loans	€1.0bn		€700m				€850m ³
Convertible Bonds	€500m						
Equity	€400m						

¹ October 2023: CHF 275m (equivalent to €284m) 2023-2028 bond issued by Fresenius SE & Co. KGaA

² October 2023: €500m 2023-2030 bond issued by Fresenius SE & Co. KGaA

³ May 2023: €850m sustainable Schuldschein loan, consisting of 6 tranches with maturities of 3, 5 and 7 years, issued by Fresenius SE & Co. KGaA

FMC: Accounting effects in Q3/23 due to IFRS 5 application

2023

JULY 14:
EGM

- **Change of legal form approved** by shareholders of FMC
- Trigger for IFRS 5 accounting and initial **impairment test**
- **No P&L valuation effect** due to FMC's market capitalization being above consolidated shareholders' equity of FMC

SEP. 30:
Q3

- Subsequent measurement under **IFRS 5**
- P&L valuation effect of ~€2 bn given FMC's market capitalization below consolidated shareholders equity of FMC
- **Thereof -€0.6 bn** attributable to **shareholders of Fresenius SE**
- **Cash-neutral** and reported as a **special item**

REGISTRATION OF
LEGAL FORM IN
COMMERCIAL REGISTER






- Expected to be effective by December 2023
- At equity accounting under IAS 28 starts
- Likely leading to **one-time non-cash P&L effect** due to deconsolidation

AT EQUITY
ACCOUNTING

- Ongoing **at equity accounting** under IAS 28 for FMC
- Separate line for at equity result in P&L

2023 Targets for Environment, Social, Governance (ESG) KPIs

Targets aligned with Management Board Compensation Short-term Incentive (STI) 2023

<div>Quality / Patients</div> <div> Net Promoter Score</div> <div>Net Promoter Score (NPS) is a KPI that ensures that FMC maintains excellent patient relationships and uses the patients' voice to gain strategic insights</div> <div>Target Value: 70</div>	<div>Quality / Patients</div> <div> Audit & Inspection Score</div> <div>Critical and major observations from regulatory authority's GMP inspections and major nonconformities in TÜV ISO 9001 audits in relation to the number of inspections/audits</div> <div>Target: 2.3</div>	<div>Quality / Patients</div> <div> Inpatient Quality Indicator</div> <div>Number of quality indicators achieved compared to the total number of indicators; individual target setting and measurement of achievement in Helios segments Germany and Spain</div> <div>Target Germany: 88% Target Spain: 55%</div>	<div>Quality / Patients</div> <div> Patient Satisfaction</div> <div>Degree of patient satisfaction in Vamed health care facilities and the patient' satisfaction with the overall services provided in VAMED health care facilities.</div> <div>Target: 1.7</div>	
<div>Employee Engagement Index</div> <div></div>	<div>Employee Engagement Index (EEI) describes how positively employees associate themselves with the employer, how committed they feel and how engaged they are at work.</div>			<div>Target: 4.33</div>

Fresenius' sustainability strategy overview

We have identified six material topic clusters and 15 individual topics in our materiality analysis

Well-being of the patient

- Patient and product safety
- Access to healthcare and medicine



Digital Transformation & Innovation

- Digital transformation and innovation
- Cybersecurity



Employees

- Working conditions, recruitment and employee participation
- Employee development
- Occupational health and safety



Diversity

- Diversity and equal opportunities



Compliance & Integrity

- Compliance
- Data protection
- Human rights
- Supply chain



Environment

- Water management
- Waste and recycling management
- Climate protection – energy and emissions



Strategy and management

We are committed to being a socially and environmentally responsible corporate player in the global healthcare market, we hereby:

- Commit to the highest quality in products, treatments, and services
- Aim to be perceived as an attractive employer to acquire talent, retain employees, and allow them to further develop their skills
- Adhere to high ethical standards and rules of good corporate governance
- Protect nature as the basis of life and treat resources with care
- Committed to respecting human rights as defined by international standards

ESG rating overview



Current score

CDP Climate: B CDP Water: C	Prime B- (as of May 24 th , 2023)	A	64/100 DJSI Europe ¹	18.2 Low Risk
--------------------------------	---	---	------------------------------------	---------------

Previous score

CDP Climate: B CDP Water: C	Prime B- (as of July 8 th , 2022)	BBB	59/100	19.7 Low Risk
--------------------------------	---	-----	--------	---------------

¹ Score date: September 23rd, 2022.

[Disclaimer \(MSCI & Sustainalytics\)](#)

Sustainable Development Goals


As a global healthcare group, Fresenius is committed to the United Nations' 17 Sustainable Development Goals

Our most important positive contribution thus relates to **SDG 3** (Good Health and Well-being). We also positively impact **SDG 4** (Quality Education) and **SDG 8** (Decent Work and Economic Growth)




Fresenius Group: Revenue Q1-Q3/23

Revenue by Region



Revenue by Business Segment



Revenue Q1-3/2023

Fresenius Kabi: Q3/23 & Q1-3/23 Organic Revenue Growth by Product Group

€m	Q3/23	Δ YoY organic	Q1-3/23	Δ YoY organic
<i>MedTech</i>	369	8%	1,113	9%
<i>Nutrition</i>	587	9%	1,803	10%
<i>Biopharma</i>	111	71%	264	59%
Growth Vectors¹	1,067	12%	3,180	11%
Pharma (IV Drugs & Fluids)	941	1%	2,833	3%
Corporate	13	--	0	--
Total revenue	2,021	7%	6,013	7%

¹ consists of MedTech, Nutrition, Biopharma

Fresenius Kabi: Q3/23 & Q1-3/23 EBIT(DA) development

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total EBITDA Margin	406 20.1%	6% +90 bps	1,209 20.1%	4% -10 bps
Growth Vectors ¹ Margin	104 9.8%	25% +180 bps	288 9.1%	+4% -30 bps
Pharma (IV Drugs & Fluids) Margin	200 21.3%	9% +150 bps	603 21.3%	7% +90 bps
Corporate	-15	--	-28	--
Total EBIT Margin	289 14.3%	6% +80 bps	863 14.4%	2% -10 bps

All figures before special items

Margin growth at actual rates

¹ consists of MedTech, Nutrition, Biopharma

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.

Fresenius Helios: Q3/23 & Q1-3/23 Key Financials

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total revenue	2,953	5%¹	9,132	6%¹
Thereof Helios Germany	1,800	4% ¹	5,451	3% ¹
Thereof Helios Spain	1,088	5% ¹	3,481	9% ¹
Thereof Helios Fertility	64	13% ¹	198	13% ¹
Total EBIT	239	8%	861	4%
Margin	8.1%	+30 bps	9.4%	-20 bps
Thereof Helios Germany Margin	157 8.7%	11% +60 bps	466 8.5%	4% 0 bps
Thereof Helios Spain Margin	81 7.4%	-2% -60 bps	392 11.3%	3% -60 bps
Thereof Helios Fertility Margin	5 7.8%	50% +130 bps	16 8.1%	13% -10 bps
Thereof Corporate	-4	33%	-13	24%

¹ Organic growth

All figures before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.

Fresenius Helios: Key Metrics

	Q1-3/23	FY/22	Δ
Helios Germany			
Hospitals	86	87	-1%
- Acute care hospitals	83	84	-1%
Beds	29,993	30,352	-1%
- Acute care hospitals	29,427	29,786	-1%
Admissions	4,143,525	5,508,158	
- patients treated in hospital	854,118	1,084,676	
- patients treated as outpatient	3,289,407	4,423,482	
Helios Spain (incl. Latin America)			
Hospitals	58	58	0%
Beds	8,267	8,259	0%
Admissions (including outpatients)	15,466,307	18,853,264	
- patients treated in hospital	850,578	1,067,410	
- patients treated as outpatient	14,615,729	17,785,854	

Fresenius Vamed: Q3/23 & Q1-3/23 Key Financials

€m	Q3/23	Δ YoY cc	Q1-3/23	Δ YoY cc
Total revenue	647	+13%	1,761	7%
Thereof organic revenue		+13%		6%
Project business	191	24%	426	5%
Service business	456	9%	1,335	7%
Total EBIT¹	10	0%	-37	--
Order intake ²	40	-74%	262	-61%
Order backlog ²			2,908 ³	-22% ⁴

¹ Before special items

² Project business only

³ Thereof conditionally agreed order backlog €839 million

⁴ Versus December 31, 2022

Fresenius Group: Calculation of Noncontrolling Interests

€m	Q1-3/23	Q1-3/22
Earnings before tax and noncontrolling interests	1,328	1,470
Taxes	-334	-326
Noncontrolling interests, thereof	-46	-72
Fresenius Kabi	-47	-52
Fresenius Helios	-14	-14
Fresenius Vamed	-2	-3
Fresenius Vamed's 23% external ownership	17	-3
Net income from operations to be deconsolidated	160	212
Net income attributable to Fresenius SE & Co. KGaA	1,108	1,284

Before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <https://www.fresenius.com/financial-results>.





Fresenius Group: Cash Flow

€m	Q3/23	Q3/23 LTM	LTM Margin	Q3 Δ YoY
Operating Cash Flow – continuing operations	648	2,084	9.3%	8%
Capex (net)	-272	-1,126	-5.0%	22%
Free Cash Flow – continuing operations	376	958	4.3%	0%
(before acquisitions, dividends and lease liabilities)				
Acquisitions (net)	-181	-237		
Dividends	1	-445		
Lease liabilities	-75	-233		
Free Cash Flow – continuing operations	121	43	0.2%	--
(after acquisitions, dividends and lease liabilities)				

Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR





€m	Q3/23	Q3/22	Q1-3/23 LTM	Q1-3/22 LTM
Operating Cash Flow	648	598	2,084	1,886
Capex (net)	-272	-223	-1,126	-1,092
Free Cash Flow	376	375	958	794
(before acquisitions and dividends)				
Special items (net income before minorities)	+35	+53	+245	+141
Interests (before special items)	+109	+67	+380	+215
Taxes (before special items)	+99	+93	+445	+481
Adjusted Free Cash Flow for CCR	619	588	2,028	1,631

Cash Flow development Q3/23

€m	Operating Cash Flow				Capex (net)				Free Cash Flow ¹			
	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin	Q3/23	Q3/22	Q3/23 Margin	Q3/22 Margin
 FRESENIUS KABI	380	301	18.8%	14.5%	-110	-118	-5.4%	-5.7%	270	183	13.4%	8.8%
 FRESENIUS HELIOS	208	353	7.0%	12.5%	-143	-90	-4.8%	-3.2%	65	263	2.2%	9.3%
 FRESENIUS VAMED	50	-18	7.7%	-3.1%	-18	-10	-2.8%	-1.8%	32	-28	4.9%	-4.9%
Corporate/Other	10	-38	--	--	-1	-5	--	--	9	-43	--	--
 FRESENIUS	648	598	11.7%	11.1%	-272	-223	-4.9%	-4.1%	376	375	6.8%	7.0%
Operations to be deconsolidated (FMC)	760	658	15.4%	12.9%	-134	-157	-2.7%	-3.1%	626	501	12.7%	9.8%

¹ Before acquisitions, dividends and lease liabilities

Cash Flow development Q3/23 LTM

€m	Operating Cash Flow				Capex (net)				Free Cash Flow ¹			
	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin	Q3/23 LTM	Q3/22 LTM	Q3/23 Margin	Q3/22 Margin
 FRESENIUS KABI	879	878	10.9%	11.5%	-472	-492	-5.8%	-6.4%	407	386	5.1%	5.1%
 FRESENIUS HELIOS	1,333	1,020	11.0%	8.8%	-590	-553	-4.9%	-4.8%	743	467	6.1%	4.0%
 FRESENIUS VAMED	-4	72	-0.2%	3.0%	-28	-50	-1.1%	-2.1%	-32	22	-1.3%	0.9%
Corporate/Other	-124	-84	--	--	-36	4	--	--	-160	-80	--	--
 FRESENIUS ²	2,084	1,886	9.3%	8.9%	-1,126	-1,091	-5.0%	-5.2%	958	795	4.3%	3.7%
Operations to be deconsolidated (FMC)	2,509	2,237	17.3%	11.7%	-632	-755	-4.4%	-3.9%	1,877	1,482	12.9%	7.8%

¹ Before acquisitions, dividends and lease liabilities

² Including FMC dividends

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q3/23

€m	Q3/23	Q3/22	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisitions	Divestitures/ Others
Fresenius Kabi	2,021	2,071	-2%	-9%	7%	7%	1%	-1%
Fresenius Helios	2,953	2,829	4%	-1%	5%	5%	0%	0%
Fresenius Vamed	647	572	13%	0%	13%	13%	0%	0%
Total	5,518	5,386	2%	-4%	6%	6%	0%	0%

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1-3/23

€m	Q1-3/23	Q1-3/22	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisitions	Divestitures/ Others
Fresenius Kabi	6,013	5,814	3%	-5%	8%	7%	2%	-1%
Fresenius Helios	9,132	8,685	5%	-1%	6%	6%	0%	0%
Fresenius Vamed	1,761	1,647	7%	0%	7%	6%	1%	0%
Total	16,621	15,862	5%	-2%	7%	6%	1%	0%

Financial Calendar / Contact

Financial Calendar

21 February 2024	Results FY/23
08 May 2024	Results Q1/24
17 May 2024	Annual General Meeting
31 July 2024	Results Q2/24
06 November 2024	Results Q3/24

Please note that these dates could be subject to change.

Contact

Investor Relations
Fresenius SE & Co. KGaA
phone: +49 6172 608-2485
e-mail: ir-fre@fresenius.com

Social Media

Follow Fresenius Investor Relations on LinkedIn:



For further information and current news: www.fresenius.com



www.twitter.com/fresenius_ir



www.linkedin.com/company/fresenius-investor-relations



#FutureFresenius